Emerging Agents in the Treatment of Rheumatic Diseases
In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.
To watch the video series component of this episode, click here.
00:00 Welcome and introductions
01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases
06:15 IL-17A, IL-17F inhibitor bimekizumab
07:42 Tyk2 inhibitor deucravacitnib in rheumatology
09:50 IL-17A inhibitor izokibep in psoriatic arthritis
11:10 Outcome measures in rheumatic diseases
16:20 Molecular signature response classifier (MSRC) test
19:40 Biosimilars in rheumatology
24:30 Precision medicine in clinical practice
29:30 Role of advanced practice practitioners in rheumatology
